Gerresheimer: Herberg looks back over almost 20 years in top managementGerresheimer: Herberg looks back over almost 20 years in top management

Announcing that he is not seeking reappointment and will leave the Management Board when his contract expires in June 2010, the CEO of Gerresheimer AG, Dr. Axel Herberg, will hand over his top job to …

Announcing that he is not seeking reappointment and will leave the Management Board when his contract expires in June 2010, the CEO of Gerresheimer AG, Dr. Axel Herberg, will hand over his top job to Uwe Rhrhoff. The Supervisory Board has received this decision with regret and in its meeting on 9 February 2010 appointed as Management Board member of many years Uwe Rhrhoff (47) Herberg“s successor. Particularly in his ten years as CEO, Herberg has shaped the Dsseldorf company“s development into an internationally leading supplier to the pharma and healthcare industry and was also instrumental in the successful flotation of Gerresheimer AG, which is now listed on the M-Dax. Herberg has worked side by side with his successor in a relationship of mutual trust for many years. Rhrhoff stands for continuity and experience at the top of the business and has already been with Gerresheimer for 20 years. He was appointed to the Management Board in 2003 and, for example, bore key responsibility for development of Gerresheimer“s important US and Chinese business. The Supervisory Board is extremely sorry that Dr. Herberg is leaving the Management Board. He has developed Gerresheimer into a very successful global supplier for the pharma industry. The Supervisory Board therefore unanimously recommends that Dr. Herberg is elected to this body. We are pleased to have Uwe Rhrhoff as the new CEO at the head of the business from the summer. Mr Rhrhoff is ideal for this position and, thanks to his extraordinary specialist knowledge and industry expertise, enjoys a high level of trust among employees and customers, said Supervisory Board Chairman Gerhard Schulze. Axel Herberg commented: The Gerresheimer Group is excellently positioned. The strategy to focus on pharma and healthcare with leading worldwide market positions has proven itself particularly during the crisis. With Uwe Rhrhoff, who I“ve worked with closely for almost twenty years, the company is in ideal hands.” In today“s meeting of the Supervisory Board, Hans-Jrgen Wiecha (47), who has been with the company for ten years, including five years on the Management Board with responsibility for finance, was also appointed as chief financial officer for a further five years.